|
|
Blood, Vol. 108, Issue 2, 685-696, July 15, 2006
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
Blood Wilson et al.
108: 685
Supplemental materials for: Wilson et al, Vol 108, Issue 2, 685-696
Files in this Data Supplement:
- Figure S1. ABI software display of dissociation curves for 249-bp NPM1 product (PDF, 188 KB) -
The horizontal axis indicates temperature, and the vertical axis is derivative. The typical dissociation curve pattern for wild-type NPM1 is illustrated in burgundy. Variant NPM1 is illustrated in blue and shows a split peak with dissociation beginning at a lower temperature.
- Figure S2. Gene expression profiles of 253 AML patients in the dataset of Valk et al5 who were examined for genes predictive of VxInsight membership based on UNM AML VxInsight ANOVA gene lists for clusters A, B, C,D, and F (PDF, 230 KB) -
Further descriptions of these findings are provided in Figures S3-S7.
- Figure S3. Gene expression among Valk et al5 AML patients for genes predictive of VxInsight cluster A (PDF, 125 KB) -
Matching U133A probe sets were found for 46 of 50 unique genes predictive of VxInsight cluster A membership. Cluster 6 of Valk et al5 had a gene expression profile most similar to VxInsight cluster A. A high percentage of patients in these 2 clusters had normal karyotypes and NPM1+ mutations (100% and 78%, respectively).
- Figure S4. Gene expression among Valk et al5 AML patients for genes predictive of VxInsight cluster B (PDF, 111 KB) -
Matching U133A probe sets were found for 46 of 50 unique genes predictive of VxInsight cluster B membership. Clusters 7 and 8 of Valk et al5 had a gene expression profile most similar to VxInsight cluster B.
- Figure S5. Gene expression among Valk et al5 AML patients for genes predictive of VxInsight cluster C (PDF, 122 KB) -
Matching U133A probe sets were found for 47 of 50 unique genes predictive of VxInsight cluster C membership. No clusters showed significant gene expression overlap with VxInsight cluster C.
- Figure S6. Gene expression among Valk et al5 AML patients for genes predictive of VxInsight cluster D (PDF, 124 KB) -
Matching U133A probe sets were found for 45 of 50 unique genes predictive of VxInsight cluster B membership. Clusters 4, 9, 10, 13, and 15 of Valk et al5 showed some genes with a similar expression pattern to VxInsight cluster D. In particular, low expression of HOXA9 and HOXA10 was observed.
- Figure S7. Gene expression among Valk et al5 AML patients for genes predictive of VxInsight cluster F (PDF, 132 KB) -
Matching U133A probe sets were found for 46 of 50 unique genes predictive of VxInsight cluster F membership. Cluster 5 of Valk et al5 had a gene expression profile most similar to VxInsight cluster F. These 2 clusters contained a predominance of monocytic leukemias. Overlap was also observed for clusters 9, 11, and 16.
- Figure S8. Gene expression profiles of 253 AML patients in the dataset of Valk et al5 who were examined for genes predictive of VxInsight membership based on UNM AML VxInsight ANOVA gene lists for clusters A, B, C, D, and F (PDF, 220 KB) -
The greatest overlap of gene expression was seen among the monocytic leukemias (FAB-M4, FAB-M5 and cluster F) in the 2 studies.
- Figure S9. Gene expression profiles of 119 AML patients in the dataset of Bullinger et al8 who were examined for genes predictive of VxInsight membership based on UNM AML VxInsight ANOVA gene lists for clusters A, B, C, D, and F (PDF, 212 KB) -
Genes predictive of the designated VxInsight clusters are listed in the columns. The rows represent the gene expression for each AML patient in the dataset of Bullinger et al8 relative to the other patients. The patients in this study formed 2 main clusters along with discrete subclusters. The data are limited by the presence of only 85 matching genes in the cDNA platform for analysis. In addition, some patients had unusable signal data for particular genes, which are colored gray. Despite these limitations, overlap of gene expression signatures is noted among the monocytic leukemias in the dataset of Bullinger et al8 and cluster F.
REFERENCES
1. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739.
2. Stirewalt DL, Mashinchi S, Kussick SJ, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124:481-484.
3. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
4. Gene Expression in Human Leukemia Experimental & Computational Methodology website. Available at: http://hsc.unm.edu/crtc/willmanresearch/Pages/UNMHSC_HPC_SNL_Methodology.htm. Accessed May 6, 2006.
5. Valk PJM, Verhaak RGW, Beijen AM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
6. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747-3754.
7. Affymetrix. Available at: http://www.affymetrix.com. Accessed May 6, 2006.
8. Bullinger L, Dohner K, Bair E, et al. Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605-1616.
9. Yeung KY, Ruzzo WL. Principal component analysis for clustering gene expression data. Bioinformatics. 2001;17:763-774.
10. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPM1c+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106:899-905.
|
|
